{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:53:45Z","timestamp":1792835625561,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00017\/3"],"award-info":[{"award-number":["MC_UU_00017\/3"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.ajkd.2025.10.004","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:44:02Z","timestamp":1761929042000},"page":"553-563.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY"],"prefix":"10.1053","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7940-386X","authenticated-orcid":false,"given":"Greco B.","family":"Malijan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Sardell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Staplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Devuyst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"N\u00e4gele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Moffat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilushi","family":"Wijayaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Killian","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Steubl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle J.","family":"Hauske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Y.A.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pontremoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Landray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Shlipak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder K.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim H.","family":"Ix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1172-8243","authenticated-orcid":false,"given":"William G.","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10365","key":"10.1053\/j.ajkd.2025.10.004_bib1","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1053\/j.ajkd.2025.10.004_bib2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"EMPA-KIDNEY Collaborative Group","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.004_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.004_bib4","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"issue":"10474","key":"10.1053\/j.ajkd.2025.10.004_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(24)02385-7","article-title":"Acute kidney injury","volume":"405","author":"Ostermann","year":"2025","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2025.10.004_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105294","article-title":"Renal tubular epithelial cells response to injury in acute kidney injury","volume":"107","author":"Li","year":"2024","journal-title":"eBioMedicine"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.004_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.004_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"Judge","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1053\/j.ajkd.2025.10.004_bib9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.004_bib10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.ajkd.2021.03.026","article-title":"The promise of tubule biomarkers in kidney disease: a review","volume":"78","author":"Ix","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.004_bib11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.2215\/CJN.0000000711","article-title":"Urine biomarkers for diabetic kidney disease progression in participants of the Chronic Renal Insufficiency Cohort Study","volume":"20","author":"Schrauben","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.004_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/jcp.36.3.253","article-title":"Alpha-1-microglobulin: an indicator protein for renal tubular function","volume":"36","author":"Yu","year":"1983","journal-title":"J Clin Pathol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.004_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40620-022-01499-3","article-title":"Elevated urinary alpha-1 microglobulin levels are associated with decreased survival among chronic kidney disease patients: a real-world population study","volume":"36","author":"Oliva-Damaso","year":"2023","journal-title":"J Nephrol"},{"issue":"316","key":"10.1053\/j.ajkd.2025.10.004_bib14","doi-asserted-by":"crossref","first-page":"316ra193","DOI":"10.1126\/scitranslmed.aac7071","article-title":"Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker","volume":"7","author":"Ju","year":"2015","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.004_bib15","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/ndt\/gfaa208","article-title":"Urinary excretion of epidermal growth factor and rapid loss of kidney function","volume":"36","author":"Norvik","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.004_bib16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrneph.2017.101","article-title":"Uromodulin: from physiology to rare and complex kidney disorders","volume":"13","author":"Devuyst","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.004_bib17","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/HYPERTENSIONAHA.122.18567","article-title":"Evolving concepts in uromodulin biology, physiology, and its role in disease: a tale of two forms","volume":"79","author":"LaFavers","year":"2022","journal-title":"Hypertension"},{"issue":"21","key":"10.1053\/j.ajkd.2025.10.004_bib18","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/j.jacc.2021.03.330","article-title":"Urinary dickkopf-3 and contrast-associated kidney damage","volume":"77","author":"Roscigno","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1053\/j.ajkd.2025.10.004_bib19","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.3390\/jcm12144705","article-title":"Patterns of dickkopf-3 serum and urine levels at different stages of chronic kidney disease","volume":"12","author":"Dziama\u0142ek-Macioszczyk","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.004_bib20","first-page":"1219","article-title":"Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology","volume":"11","author":"Song","year":"2019","journal-title":"Am J Transl Res"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.004_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/13547501003706558","article-title":"Combination of urinary kidney injury molecule-1 and interleukin-18 as early biomarker for the diagnosis and progressive assessment of acute kidney injury following cardiopulmonary bypass surgery: a prospective nested case-control study","volume":"15","author":"Liang","year":"2010","journal-title":"Biomarkers"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.004_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MNH.0000000000000186","article-title":"Monocyte chemoattractant protein-1 and the kidney","volume":"25","author":"Haller","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.004_bib23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00280-015-2880-y","article-title":"Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients","volume":"76","author":"Shinke","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.004_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002673","article-title":"Neutrophil gelatinase-associated lipocalin and contrast-induced acute kidney injury","volume":"8","author":"Quintavalle","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"13","key":"10.1053\/j.ajkd.2025.10.004_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310470","article-title":"The review of current knowledge on neutrophil gelatinase-associated lipocalin (NGAL)","volume":"24","author":"Romejko","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.004_bib26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/ijms23020647","article-title":"Biological role, mechanism of action and the importance of interleukins in kidney diseases","volume":"23","author":"Mertowska","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.004_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40620-014-0113-9","article-title":"Urine interleukin-18 in prediction of acute kidney injury: a systemic review and meta-analysis","volume":"28","author":"Lin","year":"2015","journal-title":"J Nephrol"},{"key":"10.1053\/j.ajkd.2025.10.004_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1471-2369-15-133","article-title":"Urine YKL-40 is associated with progressive acute kidney injury or death in hospitalized patients","volume":"15","author":"Hall","year":"2014","journal-title":"BMC Nephrol"},{"issue":"34","key":"10.1053\/j.ajkd.2025.10.004_bib29","doi-asserted-by":"crossref","first-page":"25803","DOI":"10.1016\/S0021-9258(19)74461-5","article-title":"Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family","volume":"268","author":"Hakala","year":"1993","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.004_bib30","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.kint.2021.08.032","article-title":"Mendelian randomization to assess causality between uromodulin, blood pressure and chronic kidney disease","volume":"100","author":"Ponte","year":"2021","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.004_bib31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume":"37","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.004_bib32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.kint.2022.12.027","article-title":"Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors","volume":"103","author":"Chapman","year":"2023","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2025.10.004_bib33","author":"Malijan"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.004_bib34","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2215\/CJN.13341215","article-title":"Effect of processing delay and storage conditions on urine albumin-to-creatinine ratio","volume":"11","author":"Herrington","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.004_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/sim.4780110204","article-title":"Statistical validation of intermediate endpoints for chronic diseases","volume":"11","author":"Freedman","year":"1992","journal-title":"Stat Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.004_bib36","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/hc1002.105136","article-title":"Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?","volume":"105","author":"Simes","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2025.10.004_bib37","series-title":"Uromodulin: Biomarker for Kidney Tubular Function","author":"Youhanna","year":"2017"},{"key":"10.1053\/j.ajkd.2025.10.004_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev-physiol-031620-092817","article-title":"Uromodulin: roles in health and disease","volume":"83","author":"Schaeffer","year":"2021","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.004_bib39","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.kint.2021.09.019","article-title":"UMOD-ulating CKD risk: untangling the relationship between urinary uromodulin, blood pressure, and kidney disease","volume":"100","author":"Turner","year":"2021","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.004_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183343","article-title":"Alternative splicing of uromodulin enhances mitochondrial metabolism for adaptation to stress in kidney epithelial cells","volume":"135","author":"Nanamatsu","year":"2025","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.004_bib41","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.cmet.2024.02.015","article-title":"Transcriptomic, epigenomic, and spatial metabolomic cell profiling redefines regional human kidney anatomy","volume":"36","author":"Li","year":"2024","journal-title":"Cell Metab"},{"issue":"7970","key":"10.1053\/j.ajkd.2025.10.004_bib42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-023-05769-3","article-title":"An atlas of healthy and injured cell states and niches in the human kidney","volume":"619","author":"Lake","year":"2023","journal-title":"Nature"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.004_bib43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/ndt\/gfaa003","article-title":"Dickkopf 3-a novel biomarker of the \u201ckidney injury continuum\u201d","volume":"36","author":"Schunk","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"7-8","key":"10.1053\/j.ajkd.2025.10.004_bib44","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00424-017-2018-7","article-title":"The hormetic functions of Wnt pathways in tubular injury","volume":"469","author":"Gr\u00f6ne","year":"2017","journal-title":"Pflugers Arch"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.004_bib45","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/ejhf.2578","article-title":"Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced","volume":"24","author":"Zannad","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.004_bib46","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ejhf.3136","article-title":"Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved","volume":"26","author":"Rastogi","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.004_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.10.004_bib48","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1681\/ASN.2013070781","article-title":"Common variants in UMOD associate with urinary uromodulin levels: a meta-analysis","volume":"25","author":"Olden","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.004_bib49","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1681\/ASN.2021040491","article-title":"Meta-GWAS reveals novel genetic variants associated with urinary excretion of uromodulin","volume":"33","author":"Joseph","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.10.004_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2025.09.009","article-title":"Glucose interference in urine biomarkers and implications for sodium-glucose cotransporter 2 inhibition","author":"Malijan","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.004_bib51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1681\/ASN.0000000000000271","article-title":"Effects of empagliflozin on fluid overload, weight, and blood pressure in CKD","volume":"35","author":"Mayne","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.004_bib52","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/dom.15249","article-title":"Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565 years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)","volume":"25","author":"Yabe","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625011072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625011072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:19:36Z","timestamp":1773929976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625011072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0272638625011072"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.10.004","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}